Skip to main content

Table 4 Complications, treatment, and prognosis of patients with COVID-19

From: Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19

Variables

All Patients (n = 550)

Severe (n = 178)

Non-severe (n = 372)

p value

Complications n, %

 Acute myocardial injury

111(20.2%)

76(42.7%)

35(9.4%)

< 0.001

 Secondary infection

110 (20.0%)

82(46.1%)

28(7.5%)

< 0.001

 ARDS

69 (12.5%)

69(38.8%)

0

< 0.001

 Acute kidney injury

45 (8.2%)

33(18.5%)

12(3.2%)

< 0.001

 Shock

40 (7.3%)

39(21.9%)

1(0.3%)

< 0.001

 DIC

20(3.6%)

11(6.2%)

9(2.4%)

0.028

Treatment n.%

 Antiviral therapy

449 (81.6%)

162(91.0%)

287(77.2%)

< 0.001

 Antibacterial therapy

  one kind

204 (37.1%)

40(22.5%)

164(44.1%)

< 0.001

   ≥ two kinds

231(42.0%)

136(76.4%)

95(25.5%)

< 0.001

 Antifungal therapy

10(1.8%)

8(4.5%)

2(0.5%)

0.004

 Glucocorticoids therapy

191(34.7%)

122(68.5%)

69(18.5%)

< 0.001

Immunotherapy

 Human immunoglobulin

52(9.5%)

23(12.9%)

29(7.8%)

0.055

 Thymosin

10(1.8%)

6(3.4%)

4(1.1%)

0.123

Vasoactive drug

34(6.2%)

34(19.1%)

0

< 0.001

 CRRT

2(0.4%)

2(1.1%)

0

0.104

Respiratory support-no.%

 Nasal catheter/Mask oxygen

477(86.8%)

105(59.0%)

372(100.0%)

< 0.001

 High-flow nasal cannula

5 (0.9%)

5(2.8%)

0

< 0.001

 Noninvasive ventilation

32 (5.8%)

32(18.0%)

0

< 0.001

 Invasive ventilation

36 (6.5%)

36(20.2%)

0

< 0.001

 ECMO

0

0

0

–

prognosis-no.%

 Transfer

24 (4.4%)

16 (9.0%)

8 (2.2%)

< 0.001

 Improved

474 (86.1%)

110 (61.8%)

364 (97.8%)

< 0.001

 Death

52(9.5%)

52(29.2%)

0

< 0.001

     Multiple system and organ failure

33/52 (63.5%)

33/52 (63.5%)

–

–

     Respiratory failure

16/52 (30.8%)

16/52 (30.8%)

–

–

     Circulatory failure

2/52 (3.8%)

2/52 (3.8%)

–

–

     Septic shock

1/52 (1.9%)

1/52 (1.9%)

–

–

Negative conversion time of RNA Detection, Median (IQR)-days

10 (6–16)

13 (8–18)

9 (6–16)

0.016

Length of hospital stay, Median (IQR)-days

16 (9–26)

22 (13–30)

15 (9–22.75)

< 0.001